Relief Therapeutics is a Covid-19 Play that Delta Will Help

We recently found out that Delta is 40-60% more contagious than Alpha. $RLFTF is up 34% in the last month up to $0.27. Delta becoming the global dominant VOC means things will get very bad in the Fall of 2021. We don’t quite yet know how bad. The increase in hospitalizations worldwide could be dramatic.

Relief Therapeutics is a small Swiss biotech company that has an important solution, and we’ve covered them many times. We are confident in the data and the prospects of this company.

Its lead compound RLF-100(TM) (aviptadil) in advanced clinical development to treat COVID-19-induced respiratory disorders, announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking Emergency Use Authorization (EUA) for the use of aviptadil in the treatment of critical COVID-19 in patients with respiratory failure.

The little Swiss biotech company has a lot going on. If you think of the possible upcoming catalysts there are several possibilities:

  • EUA approval
  • Zyesami vs REMDESIVIR results
  • ACER NDA application
  • Inhaler trial results
  • Sarcoidosis trial
  • EU inhaled trial
  • Uplifting to Nasdaq

Unfortunately the advent of Delta means it will spread a lot in 2022, and our lungs might need Zyesami. What is it?

  • ZYESAMI™ is the First Investigational Medicine to Show Efficacy in a Randomized, Double-Blind, Multicenter Trial, Achieving More Instances of Recovery in Critically Ill COVID-19 Patients with Respiratory Failure, Compared to Placebo.
  • ZYESAMI™ Demonstrated a Significant Treatment Advantage and Shortened Hospitalization in Patients Already Treated with All Approved Therapies for Critical COVID-19.

Okay so NeuroRx doesn’t know how to write or do PR, but who cares. We know the product of $RLFTF will go mainstream as a Covid-19 therapy in the ICU and likely even before for patients.

Few Micro Cap Biotech Opportunities like this in 2021

OTC biotech can be some of the biggest movers. $RLFTF has had a weird last few months, with a range of $0.04 to $0.80. Their pipeline is however like a company that is worth around $2. The Covid-19 play is a very big deal and could spike their price much higher than that.

With Delta leading to more hospitalization we’re going to need all the help we can get. The application with U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for ZYESAMI™ (Aviptadil-acetate), to treat Critically Ill COVID-19 patients suffering with respiratory failure may take months.

Consistent with previously announced top-line data, the study identified a statistically significant increase in the likelihood that patients treated with ZYESAMI™ would be alive and free of respiratory failure at 60 days, compared to those treated with placebo, and identified a significantly shorter median hospital stay.

Macro Stock Picture Has Suppressed OTC Micro Cap so far in 2021

The reality is penny stocks haven’t been very volatile in 2021, due to volume in crypto, the pivot from growth to value in the first half of 2021 and so forth so OTC stocks have been suppressed. It’s not just shorts, it’s the macro impact on the OTC and penny stocks in general.

When those macro conditions change, and it could be happening in mid June, I expect $RLFTF to do very well. Think of the enthusiasm $OCGN has faced, that could one day translate to this more obscure name. Especially when uplisting takes place.

Covid-19 isn’t over, with Delta and more variants on the way, it likely hasn’t even really begun. What Covid-19 becomes, hasn’t arrived yet. So any stock related to Covid-19 will still be in demand and could surge. When EUA is granted and uplisting occurs, how high can this stock consolidate? Perhaps around $4.00.

It could even be like $OCGN. $OCGN was $0.30 too in December, 2020, just 7 months later it’s $10.00 and surged well over $15. That’s a few thousand percent. $RLFTF has a real therapy vs. Covid-19, not just an inferior vaccine rights like $OCGN. It’s more significant. It could help with long Covid-19 symptoms, it could reduce morality in the ICU.

The Opportunity in $RLFTF is Significant

Given the results of trials for $RLFTF’s timeline, it’s not even a speculative stock. It’s the kind of stock you want to load up on below $0.30 and hold for a few years.

At the Last Futurist, here are some of our other favorites that we think are undervalued:

  • $TBLT
  • $JAGX
  • $TXMD
  • $MOGU
  • $GNUS
  • $EVFM
  • Just Energy
  • $LKNCY

We like the $1 to $2 range, since it’s easy to spot undervalued stocks at that price point. Stocks in the $0.20 to $1 range are more volatile can be be more lucrative but are more difficult to predict. Always do your own due diligence, this is not investing or financial advice. Always trade according to your personal situation with considerable risk mitigation.

Similar Posts